SCIENTURE HOLDINGS, INC. Research and Development Expense
SCIENTURE HOLDINGS, INC. (SCNX) reported Research and Development Expense of $1.17 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- SCIENTURE HOLDINGS, INC. research and development expense for the quarter ending 2026-06-30 was $1.17M, a 38.30% increase year-over-year.
- SCIENTURE HOLDINGS, INC. research and development expense for the quarter ending 2026-03-31 was $793.98K, a 38.16% increase year-over-year.
- SCIENTURE HOLDINGS, INC. research and development expense for the quarter ending 2025-12-31 was $368.70K, a 62.48% decline year-over-year.
- SCIENTURE HOLDINGS, INC. research and development expense for the quarter ending 2025-09-30 was $169.34K, a 86.50% decline year-over-year.
- SCIENTURE HOLDINGS, INC. research and development expense for fiscal 2025 was $1.96M, a 12.54% decline from fiscal 2024.
- SCIENTURE HOLDINGS, INC. research and development expense for fiscal 2024 was $2.24M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.17M 10-Q · filed 2026-08-13 | $1.96M 10-Q · filed 2026-08-13 | $2.33M derived: sum of 3 quarters · filed 2026-08-13 | $2.50M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $793.98K 10-Q · filed 2026-05-15 | $1.16M derived: sum of 2 quarters · filed 2026-05-15 | $1.33M derived: sum of 3 quarters · filed 2026-05-15 | $2.18M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $368.70K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $538.04K derived: sum of 2 quarters · filed 2026-03-30 | $1.38M derived: sum of 3 quarters · filed 2026-08-13 | $1.96M 10-K · filed 2026-03-30 |
| 2025-09-30 | $169.34K 10-Q · filed 2025-11-12 | $1.01M derived: sum of 2 quarters · filed 2026-08-13 | $1.59M 10-Q · filed 2025-11-12 | $2.57M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $843.55K 10-Q · filed 2026-08-13 | $1.42M 10-Q · filed 2026-08-13 | $2.40M derived: sum of 3 quarters · filed 2026-08-13 | $3.65M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $574.68K 10-Q · filed 2026-05-15 | $1.56M derived: sum of 2 quarters · filed 2026-05-15 | $2.81M derived: sum of 3 quarters · filed 2026-05-15 | |
| 2024-12-31 | $982.71K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.24M derived: sum of 2 quarters · filed 2026-03-30 | $2.24M 10-K · filed 2026-03-30 | |
| 2024-09-30 | $1.25M 10-Q · filed 2025-11-12 | $1.25M 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |